Management volunteers specific, checkable numbers about the near future — quantified forward commitments it could visibl
The model's full reasoning — Q3 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否自愿提供了具体的、可核查的近期数字或日期,并承诺业务将实现增长或提升。 关键点: - 管理层是否自愿提供具体数字(如产量、日期、水平)? - 这些数字是否在近期(约一年内)可验证? - 是否描述为从当前水平提升(而非持平或下降)? - 是否基于已在进行中的事项(如建设进度、订单等)? 在记录中,Mark Bristow 提到: - 黄金和铜产量环比增长,但全年黄金产量预计略低于指导区间下限(4.2-4.6百万盎司)。 - 对于Pueblo Viejo(PV)项目,尽管爬坡较慢,但预计2024年产量将超过80万盎司。 - 对于RekoDiq,预计2028年首次生产,但那是远期。 - 对于Lumwana,预计2026年首次生产,也是远期。 - 对于Goldrush,预计年底前获得记录决定,但那是许可,不是产量承诺。 - 对于Porgera,预计年底前重启,但未给出具体产量数字。 管理层是否给出了具体的、近期的、可验证的承诺?例如,2024年PV产量超过80万盎司,这是一个具体数字,且是近期(2024年),但这是否是“提升”?当前PV产量在2023年第三季度为79,000盎司(季度),年化约31.6万盎司,但2024年目标80万盎司是显著提升。然而,管理层是否将其作为承诺?他说“我们仍然期望该矿在2024年超过80万盎司”,这似乎是承诺,但语气是“期望”,且没有给出具体日期或更细的数字。另外,全年黄金产量指导略低于低端,这是下调,不是提升。 其他数字如“30%增长”是到2030年的长期目标,不是近期。 管理层是否自愿提供了具体的、可核查的近期数字?似乎没有。他们给出了全年指导,但那是常规指导,且是下调。对于PV,给出了2024年80万盎司的目标,但这是对现有项目的恢复,且是“期望”,不是强承诺。而且,这更像是恢复到一个正常水平,而不是从当前水平提升?当前PV产量因爬坡问题较低,2024年目标80万盎司是恢复,但相对于2023年实际产量是提升,但相对于原计划是下调。 另外,管理层提到“我们预计第四季度产量将进一步提高”,但没有具体数字。 因此,没有看到管理层自愿提供具体的、可核查的、近期的、描述为提升的承诺。他们给出了指导,但那是常规的,且是下调。对于PV,给出了一个数字,但那是恢复,且是“期望”,不是强承诺。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| DXLG | Destination XL Group, Inc. | Q2 2023 | 2023-08-24 | D |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SQM | Sociedad Química y Minera de Chile S.A. | Q1 2022 | 2022-05-19 | C+ |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
TWO · Q2 2022 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term that show a step-up, grounded in things they can already see....YES The transcript shows management volunteering a concrete, checkable commitment on the RoundPoint acquisition: they expect incremental annual pre-tax earnings of approximately $20 million once the portfolio is fully transferred (with Mary Riskey later confirming $0.45 per share after-tax accretion). They also state they will begin transitioning loans to Round Point as a subservicer later this year and expect the acquisition to close in 2023. These are presented as owned expectations tied to the in-house servicing model they are already executing, describing a clear step-up in earnings and operational activity above the current subservicing level.
CUBI · Q3 2018 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term, presenting them as commitments for a step-up from current le...YES Management volunteers concrete, checkable commitments for the near term (next 12–18 months) that describe a clear step-up from current levels and are grounded in things already in motion or in hand. Examples include: - NIM target of 2.75% within 12–18 months, explicitly tied to 3–4 rate hikes and the $495 million securities sale plus $500 million borrowings repayment already executed. - $600 million core-franchise deposit growth + $500–600 million CB digital + $500 million BankMobile white-label deposits next year, building on the $1.
ADPT · Q4 2022 → YESThe question is: Does management volunteer specific, checkable numbers or dates about what the company's own business will do in the near term — quantified forward commitments concrete enough that inv...YES Management volunteers concrete, checkable commitments for 2023 that describe a clear step-up: full-year revenue of $205–215 million (versus $185.3 million in 2022), clonoSEQ test volumes growing more than 50% from the current base, MRD pharma milestones in the mid to high-single-digit millions, community business reaching 20% of total revenue (from 15% currently), and 2023 OpEx (including cost of revenue) slightly below the 2022 level of $385.5 million, with average quarterly cash burn of $40 million.